Brunei Darussalam vs Indonesia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Brunei Darussalam
0.7%
in 2024
Indonesia
0.7%
in 2024
Brunei Darussalam rank
51st
Indonesia rank
51st
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Brunei Darussalam
- Indonesia
How they compare
Brunei Darussalam currently reports 0.7% against 0.7% in Indonesia, a difference of 0.0%.
Across all 10 years both countries report, Indonesia has been ahead every year.
Brunei Darussalam ranks 51st and Indonesia ranks 51st of 246 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Brunei Darussalam | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.9% | 0.9% | 0.0% | Indonesia |
| 2020s | 0.8% | 0.8% | 0.1% | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Brunei Darussalam or Indonesia?
- Brunei Darussalam, at 0.7% against 0.7% in Indonesia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Brunei Darussalam and Indonesia?
- 0.0%, with Brunei Darussalam ahead.
- How many years of comparable data are there for Brunei Darussalam and Indonesia?
- 10 years are reported by both, from 2015 to 2024.
- How do Brunei Darussalam and Indonesia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Brunei Darussalam ranks 51st and Indonesia ranks 51st of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.